logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Boston Biomedical, Inc.


USPTO Granted Patents = 19



Trademarks = 2

Forward Citations = 50

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Chiang Jia Li (18 out of 57 patents)

silverMedal Wei Li (13 out of 16 patents)

bronzeMedal Youzhi Li (11 out of 22 patents)

4.  David Leggett (8 out of 9 patents)

5.  Harry Rogoff (4 out of 9 patents)

6.  Ji-Feng Liu (3 out of 3 patents)

7.  Hitoshi Ban (2 out of 37 patents)

8.  Seiji Kamioka (2 out of 14 patents)

9.  Yusuke Sawayama (2 out of 7 patents)

10.  Naoaki Shimada (2 out of 26 patents)

11.  Wataru Hirose (2 out of 10 patents)

12.  Zhiwei Jiang (2 out of 9 patents)

13.  Toshihiko Sone (2 out of 3 patents)

14.  Matthew Hitron (2 out of 2 patents)

15.  Keith Mikule (2 out of 2 patents)


19 patents:

1. 10800752 - Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer (2020-10-13),
2. 10683274 - 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof (2020-06-16),
3. 10646464 - Methods for treating cancer (2020-05-12),
4. 10543189 - 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer (2020-01-28),
5. 10377731 - Compositions and methods for cancer treatment (2019-08-13),
6. 10183925 - Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer (2019-01-22),
7. 10017488 - 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof (2018-07-10),
8. 9834532 - Stat3 pathway inhibitors and cancer stem cell inhibitors (2017-12-05),
9. 9795595 - Methods for treating cancer (2017-10-24),
10. 9745278 - Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors (2017-08-29),
11. 9732055 - Compositions and methods for cancer treatment (2017-08-15),
12. 9730909 - Methods for targeting cancer stem cells (2017-08-15),
13. 9725444 - Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases (2017-08-08),
14. 9381184 - Compounds and compositions for targeting cancer stem cells (2016-07-05),
15. 9227962 - Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative (2016-01-05),
Boston Biomedical, Inc. is a biopharmaceutical company focused on the discovery and development of novel targeted therapeutics for cancer. The company uses its proprietary platform technology to identify and validate promising drug candidates, with the goal of improving the lives of patients worldwide. Their dedication to innovation and scientific excellence drives their mission to transform cancer treatment through the development of breakthrough therapies.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

19 Patents

#121 in Cambridge, MA

#1,008 in Massachusetts

#16,629 in US

#31,713 in the World

...
Cambridge, MA, United States of America

Boston Biomedical, Inc.

Forward Citations = 50

25 inventors:

goldMedal Chiang Jia Li (18 out of 57 patents)

silverMedal Wei Li (13 out of 16 patents)

bronzeMedal Youzhi Li (11 out of 22 patents)

4.  David Leggett (8 out of 9 patents)

5.  Harry Rogoff (4 out of 9 patents)

Please report any incorrect information to support@idiyas.com
Loading…